Japanese Clinical Practice Guideline for Diabetes 2019
Japanese Clinical Practice Guideline for Diabetes 2019
复制标题
DOI：
10.1007/s13340-020-00439-5
复制
发表时间：
2020-07-24
影响因子：
2.2
通讯作者：
Yoshioka, Narihito
中科院分区：
文献类型：
--
作者：
Araki, Eiichi;Goto, Atsushi;Yoshioka, Narihito
目前的指南是第6版《日本糖尿病临床实践指南》，自2004年首次发布以来，每三年修订一次，以促进糖尿病临床实践的循证、合理、高效和一致。值得注意的是，近年来糖尿病研究和临床实践取得了巨大进展，包括具有新作用机制的抗糖尿病药物的批准，以及这些药物的临床试验结果的公布，以及新的诊断和治疗设备，如连续血糖监测(CGM)和感觉增强泵(SAP)。同样，最近报道了日本大规模临床试验的结果，如J-doit 1至3和JDCP研究。此外，在过去的三年里，日本动脉粥样硬化学会和日本高血压学会及时发布了新的血脂和血压控制指南。因此，目前的指南不仅包括临床实践中的相关进展，而且包括迄今已提供的新发现和新的证据。虽然目前的指南按照与2016年版类似的思路组织，并使用相同的临床问题(CQS)和问题(Q)格式，但已对每个CQ或Q进行了密切审查以进行修订，并酌情增加了进一步的CQS或QS，以进一步促进指南在临床实践中的使用。因此，读者可参考《制定《日本糖尿病临床实践指南2019》的方法》，了解有效利用当前指南所涉及的指南制定过程的详细说明。希望该指南将被证明是临床环境中循证医学(EBM)的有用指南
The current guideline represents the 6th edition of the “Japanese Clinical Practice Guideline for Diabetes” which has been revised every three years since its first appearance in 2004 to promote evidence-based, rational, efficient and consistent clinical practice in diabetes. Of note, dramatic progress has been made in recent years in diabetes research and clinical practice, which includes approval of antidiabetic agents with novel mechanisms of action along with the publication of clinical trial results with these drugs, and novel diagnostic and therapeutic devices, such as continuous glucose monitoring (CGM) and sensoraugmented pumps (SAP). Again, results from large-scale clinical trials in Japan, such as J-DOIT 1 to 3 and JDCP studies, have recently been reported. Further, in the last three years, new guidelines for lipid and blood pressure control have been released in a timely fashion from the Japan Atherosclerosis Society and the Japanese Society of Hypertension. Therefore, the current guideline has been compiled to include not only relevant advances in clinical practice but novel findings and new lines of evidence that have been made available to date. While the current guideline has been organized along similar lines to those of the preceding 2016 edition and using the same clinical questions (CQs) and questions (Qs) format, each CQ or Q has been closely reviewed for revision and further CQs or Qs have been added as appropriate to further promote the use of the guidelines in clinical practice. Readers are, therefore, referred to the “Methods of developing the ‘Japanese Clinical Practice Guideline for Diabetes 2019’” for a detailed account of the guideline development processes involved to make effective use of the current guideline. It is hoped that the guideline will prove a helpful guide to evidence-based medicine (EBM) in clinical settings thereby